Anika Therapeutics, Inc. (ANIK) has 73 open-market insider trades by 26 insiders since 2006. Over the last six months insiders net bought $264K. The most active filer is Charles H. Sherwood, CEO & Director.
| Name | Title | Tier | Trades | Value | Last Trade |
|---|---|---|---|---|---|
| S.p.A. P&r | 10% | — | 1 | $31.1M | 2013-08-06 |
| Farmaceutici S.p.A. Fidia | 10% | — | 1 | $31.1M | 2013-08-06 |
| Charles H. Sherwood | CEODir | — | 15 | $19.3M | 2018-01-24 |
| Jeffery S. Thompson | Dir | — | 4 | $2.1M | 2023-06-14 |
| Raymond J. Land | Dir | — | 12 | $1.9M | 2021-06-16 |
| Sylvia Cheung | CFO | — | 2 | $1.4M | 2020-02-26 |
| Steve E. Wheeler | Dir | — | 3 | $1.1M | 2018-01-24 |
| Kevin W. Quinlan | CFO | — | 6 | $900K | 2013-03-27 |
| Francesco J. Luppino | COO | — | 2 | $832K | 2012-03-27 |
| Glenn R. Larsen | Dir | — | 1 | $498K | 2025-06-20 |
| Insider | Title | Type | Value | Date |
|---|---|---|---|---|
| Gary P. Fischetti | Director | Buy | $41K | 2026-08-03 |
| John B. Henneman III | Director | Buy | $73K | 2026-05-01 |
| Stephen D. Griffin | CEO & President | Buy | $150K | 2026-04-30 |
| David Colleran | EVP & General Counsel +1 | Buy | $32K | 2022-05-11 |
| David Colleran | EVP & General Counsel +1 | Buy | $40K | 2022-03-14 |
| Jeffery S. Thompson | Director | Buy | $49K |
Companies that share insiders with ANIK, and sector peers with recent insider buying. Related by who files, not by how the stocks move.
| 2022-03-11 |
| Michael L. Levitz | CFO & VP +1 | Buy | $98K | 2022-03-11 |
| Cheryl R. Blanchard | CEO & President +1 | Buy | $414K | 2022-03-11 |
| Michael L. Levitz | CFO & VP +1 | Buy | $260K | 2021-08-11 |
| John B. Henneman III | Director | Buy | $86K | 2021-05-18 |
| Raymond J. Land | Director | Sell | $85K | 2021-05-12 |
| Raymond J. Land | Director | Sell | $253K | 2020-11-10 |
| James Loerop | EVP Business Development | Sell | $44K | 2020-07-09 |
| Raymond J. Land | Director | Sell | $115K | 2020-02-26 |
| Sylvia Cheung | CFO | Sell | $1.2M | 2019-11-08 |